NECTIN4 and gastric cancer: These findings confirm that the safety of [64Cu]Cu-NOTA-EV-F(ab’)2 in both GC and NSCLC models, reinforcing its potential for further clinical development of Nectin-4 targeting in cancer diagnosis and therapy.